Posaconazole IV
Phase 2Small molecule
Merck & Co.Posaconazole IV is one of 25 small molecule programs targeting Aspergillosis. It is currently in Phase 2.
1
Indications
5
Total Trials
1
Active Trials
24
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
44 competitors in Aspergillosis
#DrugCompanyPhaseTrials
1Vfend
PPrism Pharmaceuticals
Approved
Mycamine
BBaxter Healthcare Corporation
Approved
Eraxis
VVicuron Pharmaceuticals
Approved
Noxafil
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Abelcet
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Sporanox
SSebela Pharmaceuticals Development LLC
Approved
Cancidas
FFresenius Kabi Oncology Ltd.
Approved
Diflucan
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Versed
CConrado Roberto Hoffmann Filho
Approved
Ambisome
GileadApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Immunocompromised2 trials
Aspergillosis1 trial
Invasive Fungal Infections1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Posaconazole IV. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company